Vol. 3 No. 9 (2023)
Reimbursement Recommendations

Belzutifan (Welireg)

Published September 20, 2023

Key Messages

  • CADTH recommends that Welireg should be reimbursed by public drug plans for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated nonmetastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or nonmetastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery if certain conditions are met.
  • Welireg should only be covered to treat adult patients with VHL disease who require therapy for associated nonmetastatic RCC, CNS hemangioblastomas, or nonmetastatic pNET, not requiring immediate surgery. Patients receiving Welireg should be in relatively good health.
  • Welireg should only be reimbursed if it is prescribed by specialists with expertise in VHL disease-associated tumours and if the cost of Welireg is reduced. Welireg should not be used in combination with other anti-tumour drugs.